Japan relies almost entirely on China for the APIs of β-lactam antibiotics. These drugs are essential for treating infectious diseases…
HOME > BUSINESS
BUSINESS
- Mortality Rate of Patients After Major Bleeds Significantly Lower with Dabigatran: BI
December 25, 2012
- Safety of Xarelto Found to Be “Consistent with Clinical Trial Data” in EPPV: Bayer Yakuhin
December 25, 2012
- Generic-only Companies Which Rely on Wholesales Worried About Decline in Their Relative Position with Wholesalers
December 25, 2012
- Increasing Competition in AD Drug Market; Sales of Over 240 Billion Yen Predicted by 2020
December 25, 2012
- Novartis Files for Approval of Combination Drug of Rasilez, CCB
December 21, 2012
- Nexium Dominates No.1, 2 Ranking in HP Market for 3rd Consecutive Month: Rep Track Survey
December 21, 2012
- Bayer Files for Approval of Radioactive Anticancer Agent in US and Europe
December 20, 2012
- Dolutegravir Filed for Approval in Europe, the US and Canada: Shionogi
December 20, 2012
- Sanofi’s JAK2 Inhibitor Improves Symptoms in Patients with MF in PII Trial
December 20, 2012
- Carsten Brunn to Take Over as President of Bayer Yakuhin in March 2013
December 20, 2012
- Eisai Transfers US Rights for Brain Tumor Treatment to Arbor Pharm
December 19, 2012
- Crestor Patent Upheld by US Court of Appeals for the Federal Circuit: Shionogi
December 19, 2012
- Takeda to Sell URL Pharma’s Generic Drug Business to Caraco
December 19, 2012
- Elmed Eisai, Kobayashi Kako Allegra Generics Not Launched on December 14
December 18, 2012
- Takeda Faces Generic Entry for Candesartan in US
December 18, 2012
- Eisai to Form Alliance with University College London for Drug Discovery Research
December 18, 2012
- Chugai to Adopt IFRS from FY2013
December 18, 2012
- Takeda Launches Phone Service to Support Patients’ Drug Administration
December 17, 2012
- Pfizer Specialty Care Chief Hopeful about Japan Vaccine Market, Novel RA Treatment
December 17, 2012
- AstraZeneca’s Novel RA Drug Fostamatinib Fails to Demonstrate Non-Inferiority to Humira in PIIb Study
December 17, 2012
ページ
Your company’s employer brand is your reputation as an employer and is crucial in attracting top talent. Some reputations are just not good; they may or not be deserved. That is just the perception in the market. Years ago there…
The Japanese government approved a bill to amend the Pharmaceuticals and Medical Devices (PMD) Act at its Cabinet meeting on…
Japan’s health ministry doled out regulatory approvals for a throng of new medicines on December 27 including Eli Lilly’s obesity…
Japan’s key reimbursement policy panel on December 25 approved an outline of the FY2025 drug price revision, finalizing plans to…
For the first time in many years, Japan appeared to have pivoted to a pro-innovation path with the FY2024 drug pricing reform. All eyes were apparently on this course change as seen in this year’s most-read story list, though the…
A Japanese health ministry panel discussing the generic industry structure on May 22 put together a report in which it…
The Ministry of Health, Labor and Welfare (MHLW) posted the final report compiled by its pharmaceutical regulation panel on its website on April 24, providing cases of drugs that could be exempted from all-case post marketing surveillance (PMS).The MHLW plans…
Japan’s all-important reimbursement policy panel on December 20 approved an outline of drug pricing reforms for FY2024, which enshrines a…
The Japanese health ministry’s expert panel tasked to discuss comprehensive policies for the rapid and stable supply of pharmaceuticals generally…